Talis Biomedical (NASDAQ:TLIS) Trading Down 2.7%

Talis Biomedical Co. (NASDAQ:TLIS)’s stock price dropped 2.7% during mid-day trading on Wednesday . The stock traded as low as $1.72 and last traded at $1.80. Approximately 33,176 shares were traded during mid-day trading, an increase of 119% from the average daily volume of 15,121 shares. The stock had previously closed at $1.85.

Talis Biomedical Price Performance

The company’s 50-day simple moving average is $5.45 and its 200-day simple moving average is $7.62.

Talis Biomedical (NASDAQ:TLIS) last issued its quarterly earnings data on Monday, August 19th. The company reported ($4.86) earnings per share (EPS) for the quarter. Talis Biomedical had a negative net margin of 5,784.73% and a negative return on equity of 79.74%.

Insider Activity

In other Talis Biomedical news, major shareholder Braden Michael Leonard bought 13,167 shares of Talis Biomedical stock in a transaction dated Monday, August 26th. The stock was bought at an average cost of $3.90 per share, for a total transaction of $51,351.30. Following the purchase, the insider now owns 216,736 shares in the company, valued at approximately $845,270.40. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders acquired 15,033 shares of company stock worth $58,804. 46.00% of the stock is currently owned by insiders.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.